Boston Scientific Defibrillators Receive CE Mark for Extended Longevity

   Boston Scientific Defibrillators Receive CE Mark for Extended Longevity

  PR Newswire

  PARIS, November 20, 2012

PARIS, November 20, 2012 /PRNewswire/ --

  Devices Projected to Have up to Twice the Longevity of Comparable Products

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for
increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS®
and TELIGEN® implantable cardioverter defibrillators (ICDs) and cardiac
resynchronization therapy defibrillators (CRT-Ds).The longevity projections
are based on data submitted to the European authorities and vary for each
device dependent on the model type and settings.

Projected device longevity exceeds 10 years for some models of Boston
Scientific ICDs, approaches eight years for its CRT-D devices, and is up to
double that of comparable competitive device models ^[1] . The company
supports these devices with warranties of up to 10 years*.Depending on the
model, the device warranties are also up to twice as long as other
currently-marketed comparable devices.

"We are pleased with the new labeling for our defibrillator products which
provides doctors and patients with additional assurance about the longevity of
these devices," said Michael Onuscheck, senior vice president and president of
Europe, Middle East and Africa at Boston Scientific. "Boston Scientific ICDs
and CRT-Ds benefit from our proprietary advanced battery technology. The new
battery was first introduced in the COGNIS and TELIGEN devices in 2008 and has
now been incorporated into our newest devices. This European approval confirms
the confidence already expressed earlier this year by the United Stated Food
and Drug Administration."

"Device longevity is of primary importance for patients with devices. As
patients live longer, increased device longevity can translate to fewer
replacement procedures and a lower risk of complications," said Vias Markides,
consultant cardiologist and chair of Arrhythmias, Royal Brompton and Harefield
NHS Foundation Trust, London. "Reducing re-intervention also has an important
impact on the health care economy, offering substantial savings to service
commissioners and offering operational advantages for device implanting
services. Boston Scientific ICDs and CRT-D devices have shown a substantial
increase in longevity projections, which is backed up by an impressive

* Warranties: INCEPTA and ENERGEN VR ICD: 10 years; INCEPTA and ENERGEN DR
ICD: eight years; PUNCTUA and TELIGEN ICD: seven years; INCEPTA and ENERGEN
CRT-D: six years; and PUNCTUA & COGNIS CRT-D: five years.


Part Number: 358362-006, 5-22-12; TELIGEN® 100 - PHYSICIAN'S TECHNICAL MANUAL
Part Number: 357449-010, 5-22-12; PUNCTUA™ CRT-D, ENERGEN™ CRT-D, INCEPTA™
CRT-D - PHYSICIAN'S TECHNICAL MANUAL Part Number: 358373-007, 5-22-12; COGNIS®
100-D - PHYSICIAN'S TECHNICAL MANUAL Part Number: 357483-012, 5-22-12

To view the Multimedia News Release including a video, backgrounders and
images, please click here:

Visit the Boston Scientific Longevity Website here:

For more news about Boston Scientific please follow us on Twitter
@bsc_eu_heart ( ).

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices that are used in a broad range of interventional medical
specialties. For more information, please visit: . 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are based on our
beliefs, assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or performance.
These forward-looking statements include, among other things, statements
regarding new product launches and launch cadence, regulatory approvals,
clinical trials, product performance and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from those
contemplated by the statements expressed in this press release. As a result,
readers are cautioned not to place undue reliance on any of our
forward-looking statements. 

Factors that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new product
introductions; demographic trends; intellectual property; litigation;
financial market conditions; and future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

Contact: Simonetta Balbi, +39-3387936422 (mobile), +39-0106060281 (direct), PR
and Corporate Communication EMEA, Boston Scientific, Toby
Minton, +44-2031166494 (direct), WCG,
Press spacebar to pause and continue. Press esc to stop.